From Libre Pathology
Jump to navigation Jump to search

Crizotinib a drug used to treat lung cancer. Its' trade name is Xalkori (Pfizer).[1] It is an ALK inhibitor.

Crizotinib has been largely subplanted by newer ALK inhibitors (ceritinib, brigatinib, lorlatinib) that were designed to cross the blood-brain barrier.[5]

See also


  1. URL: Accessed on: November 8, 2018.
  2. Shaw, AT.; Ou, SH.; Bang, YJ.; Camidge, DR.; Solomon, BJ.; Salgia, R.; Riely, GJ.; Varella-Garcia, M. et al. (Nov 2014). "Crizotinib in ROS1-rearranged non-small-cell lung cancer.". N Engl J Med 371 (21): 1963-71. doi:10.1056/NEJMoa1406766. PMID 25264305.
  3. Wu, YL.; Lu, S.; Lu, Y.; Zhou, J.; Shi, YK.; Sriuranpong, V.; Ho, JCM.; Ong, CK. et al. (Jun 2018). "Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer.". J Thorac Oncol. doi:10.1016/j.jtho.2018.06.012. PMID 29966800.
  4. Forde, PM.; Rudin, CM. (Jun 2012). "Crizotinib in the treatment of non-small-cell lung cancer.". Expert Opin Pharmacother 13 (8): 1195-201. doi:10.1517/14656566.2012.688029. PMID 22594847.
  5. Wrona, A. (Sep 2019). "Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed?". Cancer Radiother 23 (5): 432-438. doi:10.1016/j.canrad.2019.03.009. PMID 31331844.